Skip to content

Iovance Biotherapeutics

US · IOVA #1864 by market cap Listed 1970
12.92 -0.05 -0.35%
Live - 5344 symbols - heartbeat 564s ago · 2026-10-08 07:39
Pre-market 12.81 -0.81%
After-hours 12.88 -0.27%
Overnight 12.94 +0.19%
Market cap
5.85B
P/B
7.95
EPS
-1.09
Reader sentiment Are you bullish or bearish on IOVA?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Goldman Sachs Maintains Iovance Biotherapeutics(IOVA.US) With Sell Rating, Raises Target Price to $2
    Market Newswire · 2026/2/5
  • Rating change
    H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $9
    Market Newswire · 2026/6/4
  • Rating change
    Wells Fargo Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $14
    Market Newswire · 2026/2/26
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Actuate Therapeutics, Inc. (ACTU), Iovance Biotherapeutics (IOVA) and Otsuka Holdings Co (OtherOTSKF)
    TipRanks · 2026/4/22
  • Rating change
    Baird Downgrades Iovance Biotherapeutics(IOVA.US) to Hold Rating, Cuts Target Price to $4
    Market Newswire · 2026/2/25
  • Rating change
    Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (IOVA), Erasca (ERAS) and Tempus AI, Inc. Class A (TEM)
    TipRanks · 2026/2/25
  • Rating change
    Chardan Capital Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $16
    Market Newswire · 2026/4/11
  • Rating change
    Truist Financial Maintains Iovance Biotherapeutics(IOVA.US) With Hold Rating
    Market Newswire · 2026/2/25
  • Rating change
    TD Cowen Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $5
    Market Newswire · 2026/1/29
  • Rating change
    Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $10
    Market Newswire · 2026/2/4
  • Rating change
    A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $5 to $14
    Market Newswire · 2026/5/8
  • Rating change
    A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $5 to $11
    Market Newswire · 2026/2/25
  • Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $15
    Market Newswire · 2026/9/17
  • TD Cowen Initiates Iovance Biotherapeutics(IOVA.US) With Buy Rating, Announces Target Price $10
    Market Newswire · 2026/8/25
  • Citizens JMP Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $8
    Market Newswire · 2026/8/8
  • A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $15 to $20
    Market Newswire · 2026/9/30
  • Rating change
    Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $11
    Market Newswire · 2026/7/20
  • Rating change
    Mizuho Securities Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $11
    Market Newswire · 2026/8/18
  • Goldman Sachs Upgrades Iovance Biotherapeutics(IOVA.US) to Buy Rating, Raises Target Price to $15
    Market Newswire · 2026/9/24
  • Rating change
    A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $7 to $13
    Market Newswire · 2026/8/7

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 07:39:53 · For reference only, not investment advice and not tailored to your situation.